TickerFacts.

CASI Pharmaceuticals, Inc. (CASIF): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

-$43.81M
Year ended 2025-12-31
2020-12-31: -$52.18M2021-12-31: -$41.02M2022-12-31: -$32.83M2023-12-31: -$22.58M2024-12-31: -$38.32M2025-12-31: -$43.81M-$43.81M
2020-12-31 EBITDA (USD) 2025-12-31
Period endedEBITDAChange YoYSource filing
2025-12-31-$43.81Mn/m2026-05-15, From 2025-01-01
2024-12-31-$38.32Mn/m2026-05-15, From 2024-01-01
2023-12-31-$22.58Mn/m2026-05-15, From 2023-01-01
2022-12-31-$32.83Mn/m2025-03-31, From 2022-01-01
2021-12-31-$41.02Mn/m2024-03-28, From 2021-01-01
2020-12-31-$52.18Mn/a2023-04-26, From 2020-01-01

EBITDA at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedEBITDAChange YoY
CASI Pharmaceuticals, Inc. (CASIF)2025-12-31-$43.81Mn/m
Scynexis Inc (SCYX)2024-12-31-$37.12Mn/m
Sol-Gel Technologies Ltd. (SLGL)2025-12-31-$7.43Mn/m
NewAmsterdam Pharma Co N.V. (NAMS)2025-12-31-$225.46Mn/m
Alumis Inc. (ALMS)2025-12-31-$450.31Mn/m
Celularity Inc (CELU)2025-12-31-$54.01Mn/m
uniQure N.V. (QURE)2025-12-31-$170.59Mn/m
Cue Biopharma, Inc. (CUE)2025-12-31-$25.59Mn/m
Foghorn Therapeutics Inc. (FHTX)2025-12-31-$83.06Mn/m

Compare CASIF, SCYX, SLGL, NAMS side by side · Screen every company in Pharmaceutical Preparations ↗